רווח לפני ניכוי ריבית, מסים, בלאי ופחת: SOPHiA GENETICS SA (SOPH)

ARR growth is driven by the implementation of cloud-based genome analysis systems in clinics. SOPHiA GENETICS SA (SOPH) is developing partnerships with pharma behemoths and medical center networks to create personalized therapies. Revenues are based on B2B subscriptions for AI services in oncology. The operating profit history in cash terms demonstrates efficiency dynamics, where the metric value of 0.00 captures the current financial result.

This indicator measures net cash flow from operating activities, excluding the impact of depreciation and the cost of debt to assess real operational efficiency. The calculated EBITDA trend on GURU.Markets demonstrates how successfully SOPHiA GENETICS SA (SOPH) management is optimizing internal costs amid high demand for genomic IT solutions, allowing investors to judge the business's ability to generate profit under tight monetary policy.